Clinical Therapeutic Intelligence

Sign up for Clinical Therapeutic Intelligence updates

Biologics’ Clinical Therapeutic Intelligence Office was established to advance the company’s clinical expertise efforts as it continues to distinguish itself as a leader in pharmacy services, specifically within the oncology sector.



Clinical Therapeutic Intelligence Report – 2015 Year in Review

This issue highlights the many ground-breaking therapies approved by the U.S. Food and Drug Administration over the course of 2015. Highlights include immunotherapies, new treatment options for breast cancer patients, and financial assistance options for cancer patients. Immunotherapies declared game-changers, swept approvals in 2015 Breakthrough therapies for blood, lung and skin cancers dominated 2015 oncology… Read More

Clinical Therapeutic Intelligence Report: Special Edition

Biologics’ Clinical Therapeutic Intelligence Office was established to advance the company’s clinical expertise efforts as it continues to distinguish itself as a leader in pharmacy services, specifically within the oncology sector. Clinical Therapeutic Intelligence Report: Special Edition Nine new orals have been approved in the oncology space in 2015 year to date, with seven new… Read More

Clinical Therapeutic Intelligence Report: 2015 Mid-Year Review

Biologics’ mid-year report provides a comprehensive look into the specialty pharmacy landscape and current trends. Within oncology specifically, the FDA has approved eight new therapies and three new indications for therapies currently in market to date in 2015. 2015 approvals to date cover multiple indications, mechanisms of action Eight new orals have been approved in… Read More

Clinical Therapeutic Intelligence Report – 2014 Year in Review

Our 2014 Year in Review provides an overview of the oncology therapies approved over the last twelve months and current trends in drug development. This Report also features two of Biologics’ Oncology Board of Advisors, who provide insight on two emerging therapies. 2014 approvals include immunotherapies & first oral for ovarian cancer With eight new… Read More

Clinical Therapeutic Intelligence Report – 2014 Mid-Year Review

Biologics’ mid-year report provides a comprehensive look into the specialty pharmacy landsca… Read More

Bridging the Gaps in Patient Care: The Value of Proactive Engagement in the Specialty Care Model

A recent New York Times article, “Lost in Clinical Translation,” highlights the lack of effective communication in today’s health care delivery model.… Read More

Clinical Therapeutic Intelligence Report: Year in Review

Last year marked a productive year for oncology drug research and development, with ten new oncology drugs coming to market – two of which were granted accelerated approval by the FDA.… Read More

Preventative care medicine now covered for women with high breast cancer risk under ACA: a summary of the NCCN’s guidelines and recommendations

On January 10, 2014 it was announced that the Department of Health & Human Services (HHS) issued guidance to “clarify that under the Affordable Care Act,… Read More

Clinical Therapeutic Intelligence Report 1Q-2Q, 2013

The oncology market continues to grow with another productive year for drug development. There are 981 total drugs in the oncology pipelin… Read More